Skip to main content

Table 1 Baseline clinical characteristics of all patients

From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer

Characteristics Number of Patients (n) Percentage (%)
Age (years)
  ≥ 50 58 40.3
  < 50 86 59.7
Tumor stage
 T1–2 68 47.2
 T3–4 73 50.7
 Unknown 3 2.1
ER status
 Postive 102 70.8
 Negative 42 29.2
PR status
 Positive 114 79.2
 Negative 30 20.8
HER2 expression
 Positive 52 36.1
 Negative 92 63.9
Ki67 status
 Low expression 33 22.9
 High expression 103 71.5
 unkown 8 5.6
Subtype
 Luminal A-like 12 8.3
 Luminal B-like 108 75
 HER2 positive (non lumninal) 9 6.3
 Triple negative 15 10.4
Pathological response
 Complete response (include near pCR) 54 37.5
 Partial response 83 57.6
 Stable disease 7 4.9
 Progression disease 0 0